The research team turned to spatial transcriptomics, a technology that measures gene expression across intact tissue sections while preserving the physical coordinates of every measurement. Unlike single-cell RNA sequencing, which dissociates tissue and loses positional information, spatial transcriptomics allows researchers to ask not only which genes are active, but where. The investigators applied this approach to tumor samples containing TLS and used a computational framework called EcoTyper to infer cell states — transcriptionally coherent subpopulations within broader cell lineages — directly from the spatial data. In total, they identified 71 distinct cell states spanning all of the major immune lineages present in the tumor microenvironment, from B cells and T cells to dendritic cells and neutrophils.

This cell state-level resolution proved to be the study’s decisive methodological choice. When the researchers examined how each inferred state was distributed along a gradient running from the geometric core of a TLS to its surrounding periphery, they found that cells belonging to the same lineage could behave in dramatically different ways. Some lineages contained states that were enriched within the TLS and others that were depleted there, meaning that a coarse analysis lumping all cells of a lineage together would have averaged away the very patterns the researchers were seeking. Core-periphery organization, the authors conclude, is in an important sense invisible at the cell type level and only emerges at the cell state level.

Among the most notable discoveries were two TLS-enriched CD4 T cell states with clearly distinct marker gene programs. Although both belonged to the helper T cell lineage and both accumulated within tertiary lymphoid structures, they carried different transcriptional signatures, suggesting they perform different functions within the immune hub. One of these states, designated CD4.T_S02, was more abundant toward the geometric core of the TLS, while its counterpart occupied more peripheral positions. This kind of fine-grained spatial segregation within a single lineage hints at a division of labor inside TLS that mirrors, in miniature, the zoned organization of canonical lymphoid organs such as lymph nodes and the spleen.

To complement the abundance-gradient analysis, the team constructed weighted chemokine networks centered on three key signaling molecules: CXCL13, CXCL12, and the paired chemokines CCL19 and CCL21. Chemokines are the trafficking signals of the immune system, guiding cells to their destinations through gradients and receptor-ligand matching. CXCL13 and CCL19/21 are classically associated with lymphoid organization — they recruit B cells and helper T cells into structured aggregates and help maintain the boundary between distinct lymphoid zones — while CXCL12 has been implicated in both lymphoid organization and immunosuppressive niches. By mapping how these chemokine signals relate to the inferred cell states across space, the researchers could ask whether the transcriptional picture of TLS organization was corroborated by an independent, signaling-centered lens.

It was. The chemokine network analysis revealed two recurrent communities of cell states. The first was a lymphocyte activation community confined to the TLS themselves, consistent with the idea that the core of these structures is where immune cells are being primed and activated. The second was an effector-focused community that extended outward into the surrounding tumor tissue, suggesting that TLS do not merely house immune activity but actively export it — dispatching armed effector cells into the tumor proper, where they can encounter and attack malignant cells. This core-to-periphery functional gradient provides a mechanistic rationale for the clinical association between TLS presence and better outcomes: a tumor with well-organized TLS is not just decorated with immune cells, it is plugged into a production line for antitumor immunity.

One of the most intriguing recurring characters in this spatial drama was a neutrophil cell state of tentative identity that appeared as a hub across all three chemokine axes the researchers examined. Neutrophils are usually cast as short-lived, blunt instruments of innate immunity, and in many tumors they are associated with immunosuppression. The repeated emergence of a neutrophil state at the center of TLS-associated chemokine networks raises the possibility that a specialized neutrophil population may play an architectural or regulatory role within these structures — perhaps helping to organize the recruitment of lymphocytes, or modulating the signals that keep the TLS intact. The authors are careful to label this state’s identity as tentative, and defining it precisely will be a task for future work, but its centrality across independent analyses makes it one of the study’s most provocative leads.

Taken together, the two analytical strategies — the TLS-centric abundance gradient and the weighted chemokine networks — converge on a coherent model. Tertiary lymphoid structures, in this view, are spatially zoned organs: an active core where lymphocyte activation and germinal center-like processes dominate, surrounded by a more diffuse effector periphery where armed immune cells transition into the tumor tissue. The zones are not arbitrary; they are organized through a shared, key set of chemokine signaling pathways, with CXCL13, CXCL12, and CCL19/21 acting as the molecular mortar that holds the architecture in place. This zoned model reframes TLS from static histological features into dynamic, functionally compartmentalized machines for generating and deploying antitumor immunity.

The implications for cancer medicine are considerable. TLS are already the subject of intense interest as biomarkers for immunotherapy response, and numerous clinical efforts aim to induce or mature them in tumors that lack them. The new findings suggest that such efforts should be evaluated not simply by whether TLS appear, but by whether they acquire the correct internal organization — the right cell states in the right places, wired together by the right chemokine signals. A disorganized aggregate of lymphocytes may not function like a properly zoned TLS, and therapies that reshape chemokine signaling could, in principle, convert poorly structured infiltrates into fully functional immune hubs. The cell state atlas generated in this study offers a reference against which such interventions could be measured.

The study, conducted under ethics approvals from the University of Tokyo and Keio University School of Medicine and supported by JSPS KAKENHI grants, also demonstrates the maturing of spatial transcriptomics as a discovery platform. By combining computational state inference with explicit spatial modeling and network analysis, the researchers extracted organizational principles that neither approach alone would have revealed. As the technology spreads and atlases of this kind accumulate across cancer types, the field moves closer to a genuinely spatial understanding of the tumor immune microenvironment — one in which the arrangement of cells, not merely their presence, becomes a target of measurement, prediction, and ultimately therapy. For now, the message of this work is clear: to understand how tumors’ hidden immune organs work, one must look not just at who is there, but at who is where, and at the chemical conversations that put them there.

Subject of Research: Spatial organization and chemokine network architecture of tertiary lymphoid structures in tumors

Article Title: Spatial transcriptomics reveals cell state-level organization and chemokine network architecture within tertiary lymphoid structures

Article References: Yan, A., Iwasawa, T., Tanaka, N., Kakimi, K., Lysenko, A., & Tsunoda, T. (2026). Spatial transcriptomics reveals cell state-level organization and chemokine network architecture within tertiary lymphoid structures. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04529-2

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04529-2

Keywords: tertiary lymphoid structures, spatial transcriptomics, chemokine signaling networks, cell states, tumor microenvironment, cancer immunology, CXCL13, CXCL12, CCL19, CD4 T cells, neutrophils, immunotherapy biomarkers

The research focused on a question that has long frustrated oncologists and immunologists alike: not simply which immune cells are present in a tumor, but where they are located and whom they are talking to. Bulk sequencing of tumors averages out the spatial information that increasingly appears to govern immune behavior. To overcome this limitation, the team performed spatial transcriptomic sequencing on primary hepatocellular carcinoma tissues obtained from patients with and without portal vein tumor thrombus, an aggressive manifestation of the disease in which tumor cells invade the main drainage vein of the liver. By preserving the physical coordinates of gene expression across tissue sections, the technique allowed the researchers to reconstruct a topographic map of each tumor, distinguishing tumor cores from stromal regions and invasive borders.

The maps revealed a clear regional logic. In non-metastatic tumors, the stromal compartments and the borders between tumor and healthy tissue showed heightened immune activity compared with tumor cores. These regions were enriched for tertiary lymphoid structures, organized aggregates of immune cells that function like improvised lymph nodes inside tissues and are increasingly associated with better responses to immunotherapy. Crucially, the spatial data showed that cancer-associated fibroblasts and B cells were not scattered randomly through the tissue but co-localized in the same neighborhoods, suggesting an active, structured relationship rather than coincidental overlap.

To identify the molecular language underlying that relationship, the researchers applied cell communication analysis to their spatial dataset. One signaling pair stood out: the chemokine CCL19, produced by a subset of fibroblasts, and CXCR3, its receptor on a subset of B cells. CCL19 is best known for orchestrating immune cell traffic in lymph nodes and in tertiary lymphoid structures, guiding circulating immune cells to precise anatomical destinations. The analysis indicated that CCL19-positive fibroblasts act as beacons, drawing CXCR3-positive B cells into stromal and peritumoral niches where the B cells can exert antitumor effects. The pattern was consistent across the spatial data and was independently supported by public single-cell RNA sequencing datasets, which confirmed the coexistence of the two cell populations in human hepatocellular carcinoma.

Correlation, however, is not causation, so the team turned to experimental models. In a subcutaneous hepatoma mouse model, the researchers confirmed that fibroblast-derived CCL19 promoted B cell infiltration into tumors and suppressed tumor growth in a manner dependent on CXCR3. To isolate the contribution of the chemokine itself, they engineered a fully murine validation system by co-inoculating Hepa1-6 liver cancer cells with either control fibroblasts or fibroblasts engineered to overexpress murine CCL19. Tumors containing the CCL19-producing fibroblasts grew significantly more slowly and harbored markedly more tumor-infiltrating B cells than controls. When the researchers blocked CXCR3 with a neutralizing antibody, both effects were partially reversed: B cell infiltration dropped and tumor growth resumed. The result established a functional, receptor-dependent mechanism rather than a mere statistical association.

The clinical implications emerged from multiplex immunofluorescence staining, a technique that labels multiple proteins simultaneously in tissue sections, applied across multi-center clinical cohorts of hepatocellular carcinoma patients. The staining demonstrated that the abundance of CCL19-positive cancer-associated fibroblasts and the infiltration of CXCR3-positive B cells were positively correlated in patient tumors, mirroring the mouse experiments. More strikingly, patients whose tumors contained high levels of both cell populations survived significantly longer than patients whose tumors lacked this co-infiltration. The paired signature behaved as a prognostic biomarker, suggesting that pathologists could one day use a simple two-marker stain to stratify patients by the immune geography of their tumors.

The study carries particular weight because it reframes the role of cancer-associated fibroblasts. These cells, which arise largely from activated hepatic stellate cells in the liver, have historically been cast as villains in tumor biology: they remodel the extracellular matrix, secrete growth factors, and build physical and immunosuppressive barriers that keep effector T cells out of tumor cores. The new findings do not erase that darker reputation, but they demonstrate that a specific fibroblast subset, defined by CCL19 expression, performs a genuinely antitumor function by organizing B cell recruitment. This kind of functional specialization within the fibroblast compartment underscores why broad anti-fibroblast strategies have struggled in clinical trials and why precision targeting of specific fibroblast states may prove more fruitful.

The work also elevates B cells within the hierarchy of tumor immunology. Most cancer immunotherapy research and clinical development have centered on cytotoxic T cells, leaving B cells comparatively understudied in solid tumors. Evidence has been accumulating that B cells within tertiary lymphoid structures can support antitumor immunity, present antigen, and produce antibodies, but their spatial regulation inside liver tumors has remained murky. By tying B cell localization to a fibroblast-derived chemokine gradient, the study provides a mechanistic handle on how tumors might be engineered, or engineered therapies designed, to build productive immune niches. Pharmacological or cellular approaches that amplify CCL19 signaling in tumors, or that expand CXCR3-positive B cell populations, could in principle convert immunologically cold hepatocellular carcinomas into more inflamed, treatment-responsive ones.

The researchers acknowledge that the axis is one module within a far more complex ecosystem. Portal vein tumor thrombus, the aggressive phenotype included in their spatial analysis, showed distinct regional features compared with non-metastatic tumors, and the interplay between the CCL19-CXCR3 axis and other immune pathways, including T cell checkpoints, remains to be fully charted. Nevertheless, the convergence of spatial transcriptomics, single-cell validation, functional mouse modeling, and multi-center clinical correlation gives the finding an unusually strong evidentiary foundation. For a disease with limited systemic options and stubborn resistance to immunotherapy in most patients, the identification of a fibroblast-to-B cell antitumor axis offers both a measurable biomarker today and a plausible therapeutic target for tomorrow. The study, published open access in the Journal of Translational Medicine, was supported by the National Natural Science Foundation of China and provincial and municipal research programs in Jiangsu Province.

Subject of Research: Spatial transcriptomic mapping of the hepatocellular carcinoma tumor microenvironment and the antitumor CCL19-CXCR3 axis between fibroblasts and B cells.

Article Title: Topographic mapping of the HCC microenvironment reveals an antitumor axis between CCL19+ fibroblasts and CXCR3+ B Cells

Article References: Gan, X., Liang, Y., Deng, Z., Li, G., Wei, W., Shen, D., Xu, Y., Yang, X., Sun, D., Qiu, J., Huang, Z., Zhu, Y., Qin, L., Zhang, Z., Tang, Z., Zhang, W., & Lu, Y. (2026). Topographic mapping of the HCC microenvironment reveals an antitumor axis between CCL19+ fibroblasts and CXCR3+ B Cells. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08800-z

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08800-z

Keywords: hepatocellular carcinoma, tumor microenvironment, spatial transcriptomics, cancer-associated fibroblasts, B cells, CCL19, CXCR3, tertiary lymphoid structures, liver cancer, prognosis, immunotherapy, tumor immunology

The study, led by Indri Desiati and May-Britt Tessem of the Norwegian University of Science and Technology together with colleagues at Oslo University Hospital and St. Olavs Hospital, focused on 223 men drawn from two independent cohorts: 136 patients from Trondheim and 87 from Oslo. Each patient provided a serum sample before surgery, and the researchers measured the levels of proteins involved in inflammation and immuno-oncology using the Olink platform, a proximity extension assay technology capable of quantifying hundreds of proteins from tiny volumes of blood with high sensitivity and specificity. Thirty-four proteins overlapped between the inflammation and immuno-oncology panels and were analyzed across the combined cohort.

The clinical questions at the heart of the study are among the most consequential in prostate cancer management. Biochemical recurrence was defined as a PSA level of 0.2 nanograms per milliliter or higher following surgery, a signal that prostate tissue, or possibly residual or metastatic cancer cells, is once again producing the enzyme. PSA persistence, defined as a PSA level of 0.1 nanograms per milliliter or higher, indicates that PSA never fully fell after the operation, often hinting that cancerous tissue remained in the body. Both outcomes mark turning points at which patients and clinicians must decide whether additional treatment, such as radiotherapy or androgen deprivation therapy, is warranted.

Among the 34 immune proteins measured, one stood out with striking consistency. Interleukin 18, or IL18, a cytokine known to stimulate antitumor immune activity and promote the development of cytotoxic T lymphocytes and natural killer cells, was consistently lower in patients who later experienced recurrence or PSA persistence compared with those who remained disease-free. Reduced IL18 before surgery, the authors suggest, may reflect weakened antitumor immune surveillance already in place before the tumor was removed, leaving patients biologically vulnerable to regrowth.

The PSA persistence group told an even more distinctive immunological story. Patients whose PSA never dropped to undetectable levels showed lower levels of TNFSF12, also known as TWEAK, along with reduced CCL19, a chemokine that helps guide immune cells into lymphoid tissues, and lower CD244, a receptor involved in natural killer and T cell function. Perhaps most intriguingly, the researchers observed a broader trend toward reduced protein levels across the entire panel in the persistence group in both cohorts, a pattern consistent with what oncologists call an immune-desert profile, in which the tumor environment is largely devoid of active immune cell infiltration and activity.

To translate these observations into practical risk prediction, the team built protein-based classification models using partial least squares discriminant analysis with fivefold cross-validation and recursive feature elimination, then compared their performance against models built from standard clinical parameters including age, pre-surgical PSA, biopsy Gleason Grade Group, clinical tumor stage, and PI-RADS MRI scoring. The protein signatures outperformed the clinical models in both cohorts. In Trondheim, the protein model achieved an area under the receiver operating characteristic curve, or AUC, of 0.73 for recurrence compared with 0.64 for the clinical model, and 0.83 for PSA persistence compared with 0.81. In Oslo the gap was even wider: AUC values of 0.77 versus 0.54 for recurrence and 0.89 versus 0.63 for persistence.

When the researchers combined the immune protein data with clinical parameters, discrimination improved further still. The combined models reached an AUC of 0.75 for recurrence in Trondheim and 0.75 in Oslo, while for PSA persistence the combined models achieved AUC values of 0.91 in Trondheim and 0.88 in Oslo. These numbers, while requiring validation in larger independent cohorts, indicate that a simple pre-surgical blood test capturing immune signaling could meaningfully sharpen the risk picture that clinicians currently assemble from imaging, biopsy grading, and PSA measurements alone.

The technical rigor of the study strengthens confidence in its conclusions. Group comparisons were performed using one-way analysis of variance with false discovery rate correction to guard against spurious findings, and prognostic associations were evaluated with Cox proportional hazards models for recurrence and logistic regression for PSA persistence. Analyzing two geographically and administratively separate cohorts provided an internal replication of the key findings, particularly the consistent reduction of IL18 in patients destined for recurrence or persistence, and the immune-desert pattern in the persistence group.

Beyond its immediate predictive value, the study carries broader implications for the immunobiology of prostate cancer. Prostate cancer has traditionally been considered a relatively cold tumor, less responsive to the checkpoint inhibitor immunotherapies that have transformed the treatment of melanoma and lung cancer. The observation that specific, measurable immune states, one inflamed and one suppressed, are already detectable in peripheral blood before surgery suggests that systemic immune contexture plays a role in determining which tumors evade control. If confirmed, immune-proteomic profiling could help identify patients who might benefit from immunotherapeutic strategies or more aggressive adjuvant treatment, and could enrich clinical trials designed around immune biomarkers.

The authors emphasize that their findings support the potential of pre-surgical serum immune-proteomic profiling for risk stratification and treatment planning, pending further validation in larger independent cohorts. The work was funded by the Norwegian Cancer Society and the Central Norway Regional Health Authority, and the serum samples were provided through hospital biobanks with ethics approval and written informed consent from all participants. For the roughly 1.4 million men diagnosed with prostate cancer worldwide each year, the prospect of a routine blood test performed before surgery that reveals not only the tumor’s characteristics but the body’s immunological readiness to fight it represents a compelling step toward truly individualized cancer care. As proteomic technologies grow faster and cheaper, the immune fingerprint in a vial of blood may become as standard a part of the surgical workup as the MRI scan itself.

Subject of Research: Pre-surgical serum immune-proteomic biomarkers predicting recurrence after prostate cancer surgery

Article Title: Pre-surgical immune-proteomic profiles in serum identify inflamed and suppressed immune states associated with biochemical recurrence and PSA persistence in prostate cancer

Article References: Desiati, I., Bozorgpana, S., Ramberg, H., Berge, V., Tasken, K. A., Giskeødegård, G. F., Bathen, T. F., & Tessem, M.-B. (2026). Pre-surgical immune-proteomic profiles in serum identify inflamed and suppressed immune states associated with biochemical recurrence and PSA persistence in prostate cancer. Clinical Proteomics. https://doi.org/10.1186/s12014-026-09634-z

Image Credits: AI Generated

DOI: 10.1186/s12014-026-09634-z

Keywords: prostate cancer, biochemical recurrence, PSA persistence, immune biomarkers, serum proteomics, IL18, Olink, radical prostatectomy, risk stratification, immune-desert profile, TNFSF12, CCL19